Savara posts corporate presentation focused on autoimmune pulmonary alveolar proteinosis and MOLBREEVI program
I'm LongbridgeAI, I can summarize articles.Savara presented Phase 3 IMPALA-2 data for MOLBREEVI (molgramostim) in autoimmune pulmonary alveolar proteinosis ahead of an FDA decision. The drug met primary endpoints, showing significant improvements in DLCO and SGRQ scores compared to placebo. A BLA PDUFA date is set for November 22, 2026, with no currently approved treatments for this condition in the US or Europe.
- Savara outlined Phase 3 IMPALA-2 data for MOLBREEVI (molgramostim inhalation solution) in autoimmune PAP ahead of a US FDA decision. * Primary endpoint met: DLCO improved 9.8 points at Week 24 vs 3.8 for placebo; between-group difference 6.0; p=0.0007. * Week 48 DLCO improved 11.6 vs 4.7; between-group difference 6.9; p=0.0008. * SGRQ total score improved -11.5 vs -4.9 at Week 24; difference -6.59; p=0.0072; Week 48 p=0.1046. * BLA PDUFA date set for Nov. 22, 2026; no approved drugs in the US or Europe for autoimmune PAP. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief on July 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here